Advanced Search
DAI Li, ZHANG Lu, JI Hui, KONG Xiang-wen. Therapeutic effects of ZK14,a novel nitric oxide donating biphenyldicarboxylate derivative,on hepatic fibrosis in rats[J]. Journal of China Pharmaceutical University, 2009, 40(3): 254-257.
Citation: DAI Li, ZHANG Lu, JI Hui, KONG Xiang-wen. Therapeutic effects of ZK14,a novel nitric oxide donating biphenyldicarboxylate derivative,on hepatic fibrosis in rats[J]. Journal of China Pharmaceutical University, 2009, 40(3): 254-257.

Therapeutic effects of ZK14,a novel nitric oxide donating biphenyldicarboxylate derivative,on hepatic fibrosis in rats

More Information
  • Aim :To study the therapeutic effects of ZK14,a novel nitric oxide donor,on hepatic fibrosis in rats. Methods :Rats were injected intraperitoneally with CCl4 and induced to hepatic fibrosis,followed by intragasrtic administration with high dose of 20 mg/kg and low dose of 10 mg/kg of ZK14for 4 weeks.The effects were evaluated in the content of nitric oxide of serum and nitric oxide synthases of liver,in serum levels of the hepatic functions indices and hepatic fibrotic index and in liver histopathology. Results :The biochemical indices and pathology grade were effectively improved in the group of ZK14 20 mg/kg,and liver function was also effectively protected in this group. Conclusion :ZK14,a novel nitric oxide donating biphenyldicarboxylate derivative,showed preferable therapeutic effects on hepatic fibrosis of rats induced with CCl4,and it may be of potential value in the treatment of hepatic fibrosis.
  • Related Articles

    [1]ZHANG Yan, JIANG Zhenzhou, ZHANG Luyong. Ameliorative effect of psoralen on acute liver injury induced by carbon tetrachloride in mice[J]. Journal of China Pharmaceutical University, 2021, 52(5): 596-602. DOI: 10.11665/j.issn.1000-5048.20210512
    [2]CAI Yanfei, WAN Aini, CHEN Yun, JIN Jian. Anti-liver fibrosis activities of the extracellular domain of transforming growth factor beta type II receptor fusion protein in vivo[J]. Journal of China Pharmaceutical University, 2019, 50(2): 246-252. DOI: 10.11665/j.issn.1000-5048.20190217
    [3]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [4]ZHAO Limeng, WANG Shuzhen. Therapeutic applications of small molecule kinase inhibitors in liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(2): 147-157. DOI: 10.11665/j.issn.1000-5048.20180203
    [5]WAN Aini, XU Dongsheng, CAI Yanfei, CHEN Yun, JIN Jian, LI Huazhong. Anti-liver fibrosis activities of human insulin-like growth factor-1 in vitro[J]. Journal of China Pharmaceutical University, 2017, 48(4): 476-482. DOI: 10.11665/j.issn.1000-5048.20170413
    [6]Bifendate liposomes modified by bile and its role in enhancing hepatocytes uptake in vitro[J]. Journal of China Pharmaceutical University, 2010, 41(4): 342-347.
    [7]Pharmacokinetics of paeoniflorin in acute liver injury rats induced by CCl4[J]. Journal of China Pharmaceutical University, 2009, 40(1): 77-79.
    [8]Synthesis and Anti-inflammatory Activity of Nitric Oxidedonating α-Substituted p-(Methanesulfonyl)phenylpropenoic Acid Esters[J]. Journal of China Pharmaceutical University, 2004, (3): 6-10.
    [9]Influence of Qingkai Granules on the Serum Nitric Oxide and Tumor Necrosis Factor in Rat with Acute Hepatic Injure[J]. Journal of China Pharmaceutical University, 2002, (5): 89-91.
    [10]Effect of Extract of Folium Ginkgo on Perfused Rat Liver Injury Induced by CCl 4[J]. Journal of China Pharmaceutical University, 1999, (2): 49+51.

Catalog

    Article views (1200) PDF downloads (1097) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return